Departments of Cardiology, Fudan University, Shanghai, China. (Y. Zou, Z.L., J.J., Q.L., J.M.J.W., K.J., X.R., Y. Zhang, C.H., Y.X., H.G., J. Lin, J.G., Y.D ...

Lexeo Therapeutics, Inc, a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced positive interim data across all dose cohorts of ...

1 Department of Cardiology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China 2 Department of Physical Examination for Cadres, First Affiliated Hospital of Kunming ...

Background Apical hypertrophic cardiomyopathy (HCM) is a rare variant of HCM, often considered to have a benign prognosis. This study aimed to compare the clinical characteristics and genetic ...

Clinically meaningful improvements were also observed on the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), with a substantial mean increase of 23 points observed at ...

cambogia. Also possible is an acute phase of a genetic condition such as desmosomal arrhythmogenic cardiomyopathy or filamin and lamin cardiomyopathies, all of which are associated with a ...

In a recent filing with the US Securities and Exchange Commission, Tenaya said it will focus its resources on advancing TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN ...

CHICAGO – Treatment with Tenaya Therapeutics' investigational gene therapy, TN-201, for MYBPC3-associated hypertrophic cardiomyopathy (HCM) was well tolerated and led to symptom improvement, according ...

View all available purchase options and get full access to this article.